{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:07:58Z","timestamp":1768446478531,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,9,28]],"date-time":"2005-09-28T00:00:00Z","timestamp":1127865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1038\/sj.npp.1300896","type":"journal-article","created":{"date-parts":[[2005,9,28]],"date-time":"2005-09-28T16:18:57Z","timestamp":1127924337000},"page":"424-430","source":"Crossref","is-referenced-by-count":47,"title":["Plasma Drug Concentrations and Physiological Measures in \u2018Dance Party\u2019 Participants"],"prefix":"10.1038","volume":"31","author":[{"given":"Rodney J","family":"Irvine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Keane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Felgate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Una D","family":"McCann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D","family":"Callaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason M","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,9,28]]},"reference":[{"key":"BF1300896_CR1","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1056\/NEJMoa043901","volume":"352","author":"CS Almond","year":"2005","unstructured":"Almond CS, Shin AY, Fortescue EB, Mannix RC, Wypij D, Binstadt BA et al (2005). Hyponatremia among runners in the Boston Marathon. N Engl J Med 352: 1550\u20131556.","journal-title":"N Engl J Med"},{"key":"BF1300896_CR2","first-page":"687","volume-title":"Disposition of Toxic Drugs & Chemicals in Man","author":"RC Baselt","year":"2002","unstructured":"Baselt RC (2002). Disposition of Toxic Drugs & Chemicals in Man, 6th edn. Chemical Toxicology Institute: London. pp 687\u2013688."},{"key":"BF1300896_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0161-813X(03)00030-5","volume":"24","author":"JF Bowyer","year":"2003","unstructured":"Bowyer JF, Young JF, Slikker W, Itzak Y, Mayorga AJ, Newport GD et al (2003). Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or D-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. Neurotoxicology 24: 379\u2013390.","journal-title":"Neurotoxicology"},{"key":"BF1300896_CR4","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/j.1476-5381.1995.tb15037.x","volume":"115","author":"MI Colado","year":"1995","unstructured":"Colado MI, Williams JL, Green AR (1995). The hyperthermic and neurotoxic effects of \u2018Ecstasy\u2019 (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 115: 1281\u20131289.","journal-title":"Br J Pharmacol"},{"key":"BF1300896_CR5","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1046\/j.1360-0443.2002.00222.x","volume":"97","author":"JC Cole","year":"2002","unstructured":"Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA (2002). The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 97: 1531\u20131536.","journal-title":"Addiction"},{"key":"BF1300896_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s002130100727","volume":"155","author":"SD Comer","year":"2001","unstructured":"Comer SD, Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW (2001). Effects of repeated oral methamphetamine administration in humans. Psychopharmacology 155: 397\u2013404.","journal-title":"Psychopharmacology"},{"key":"BF1300896_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1046\/j.1365-2125.2000.00121.x","volume":"49","author":"R de la Torre","year":"2000","unstructured":"de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN et al (2000). Non-linear pharmacokinetics of MDMA (\u2018ecstasy\u2019) in humans. Br J Clin Pharmacol 49: 104\u2013109.","journal-title":"Br J Clin Pharmacol"},{"key":"BF1300896_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00007691-200404000-00009","volume":"26","author":"R de la Torre","year":"2004","unstructured":"de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M et al (2004). Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26: 137\u2013144.","journal-title":"Ther Drug Monit"},{"key":"BF1300896_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/09595230220119363","volume":"21","author":"LR Gowing","year":"2002","unstructured":"Gowing LR, Henry-Edwards SM, Irvine RJ, Ali RL (2002). The health effects of ecstasy: a literature review. Drug Alcohol Rev 21: 53\u201363.","journal-title":"Drug Alcohol Rev"},{"key":"BF1300896_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1124\/pr.55.3.3","volume":"55","author":"AR Green","year":"2003","unstructured":"Green AR, Mechan AO, Elliott JM, O\u2019Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, \u2018ecstasy\u2019). Pharmacol Rev 55: 463\u2013508.","journal-title":"Pharmacol Rev"},{"key":"BF1300896_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/0028-3908(96)84647-8","volume":"35","author":"MP Gygi","year":"1996","unstructured":"Gygi MP, Gygi SP, Johnson M, Wilkins DG, Gibb JW, Hanson GR (1996). Mechanisms for tolerance to methamphetamine effects. Neuropharmacology 35: 751\u2013757.","journal-title":"Neuropharmacology"},{"key":"BF1300896_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0149-7634(98)00046-3","volume":"23","author":"KM Hegadoren","year":"1999","unstructured":"Hegadoren KM, Baker GB, Bourin M (1999). 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 23: 539\u2013553.","journal-title":"Neurosci Biobehav Rev"},{"key":"BF1300896_CR13","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/jat\/20.6.432","volume":"20","author":"HJ Helmlin","year":"1996","unstructured":"Helmlin HJ, Bracher K, Bourquin D, Vonlanthen D, Brenneisen R (1996). Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Anal Toxicol 20: 432\u2013440.","journal-title":"J Anal Toxicol"},{"key":"BF1300896_CR14","first-page":"917","volume":"165","author":"H Kalant","year":"2001","unstructured":"Kalant H (2001). The pharmacology and toxicology of \u2018ecstasy\u2019 (MDMA) and related drugs. Can Med Assoc J 165: 917\u2013928.","journal-title":"Can Med Assoc J"},{"key":"BF1300896_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/00007691-200204000-00009","volume":"24","author":"T Kraemer","year":"2002","unstructured":"Kraemer T, Maurer HH (2002). Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit 24: 277\u2013289.","journal-title":"Ther Drug Monit"},{"key":"BF1300896_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.forsciint.2003.11.021","volume":"140","author":"C Lora-Tamayo","year":"2004","unstructured":"Lora-Tamayo C, Tena T, Rodriguez A, Moreno D, Sancho JR, Ensenat P et al (2004). The designer drug situation in Ibiza. Forensic Sci Int 140: 195\u2013206.","journal-title":"Forensic Sci Int"},{"key":"BF1300896_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/sj.npp.1300808","volume":"31","author":"A Mechan","year":"2006","unstructured":"Mechan A, Yuan J, Hatzidimitriou G, Irvine R, McCann U, Ricaurte G (2006). Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: Relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology 31: 339\u2013350.","journal-title":"Neuropsychopharmacology"},{"key":"BF1300896_CR18","volume-title":"The Forensic Pharmacology of Drugs of Abuse","author":"M Odell","year":"2001","unstructured":"Odell M, Drummer OH (2001). The Forensic Pharmacology of Drugs of Abuse, 1st edn, Oxford University Press: Oxford."},{"key":"BF1300896_CR19","doi-asserted-by":"publisher","first-page":"PL309","DOI":"10.1016\/S0024-3205(99)00555-X","volume":"65","author":"R Pacifici","year":"1999","unstructured":"Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN et al (1999). Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. Life Sci 65: PL309\u2013PL316.","journal-title":"Life Sci"},{"key":"BF1300896_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1749-6632.2002.tb04183.x","volume":"965","author":"R Pacifici","year":"2002","unstructured":"Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN et al (2002). Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings. Ann NY Acad Sci 965: 421\u2013433.","journal-title":"Ann NY Acad Sci"},{"key":"BF1300896_CR21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0022-3565(24)29682-8","volume":"296","author":"R Pacifici","year":"2001","unstructured":"Pacifici R, Zuccaro P, Hernandez Lopez C, Pichini S, Di Carlo S, Farre M et al (2001). Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther 296: 207\u2013215.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1300896_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/0269881105048900","volume":"19","author":"AC Parrott","year":"2005","unstructured":"Parrott AC (2005). Chronic tolerance to recreational MDMA (3,4- methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol 19: 71\u201383.","journal-title":"J Psychopharmacol"},{"key":"BF1300896_CR23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/jat\/27.8.552","volume":"27","author":"FT Peters","year":"2003","unstructured":"Peters FT, Samyn N, Wahl M, Kraemer T, De Boeck G, Maurer HH (2003). Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS. J Anal Toxicol 27: 552\u2013559.","journal-title":"J Anal Toxicol"},{"key":"BF1300896_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000026664","volume":"42","author":"GA Ricaurte","year":"2000","unstructured":"Ricaurte GA, Yuan J, McCann UD (2000). 3,4-Methylenedioxymethamphetamine (\u2018Ecstasy\u2019)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42: 5\u201310.","journal-title":"Neuropsychobiology"},{"key":"BF1300896_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0379-0738(02)00157-3","volume":"128","author":"N Samyn","year":"2002","unstructured":"Samyn N, De Boeck G, Wood M, Lamers CT, De Waard D, Brookhuis KA et al (2002). Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. Forensic Sci Int 128: 90\u201397.","journal-title":"Forensic Sci Int"},{"key":"BF1300896_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/bmj.326.7380.80","volume":"326","author":"F Schifano","year":"2003","unstructured":"Schifano F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse AH (2003). Review of deaths related to taking ecstasy, England and Wales, 1997\u20132000. BMJ 326: 80\u201381.","journal-title":"BMJ"},{"key":"BF1300896_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0006-8993(85)90748-6","volume":"343","author":"CJ Schmidt","year":"1985","unstructured":"Schmidt CJ, Gehlert DR, Peat MA, Sonsalla PK, Hanson GR, Wamsley JK et al (1985). Studies on the mechanism of tolerance to methamphetamine. Brain Res 343: 305\u2013313.","journal-title":"Brain Res"},{"key":"BF1300896_CR28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.addbeh.2004.02.022","volume":"29","author":"AB Scholey","year":"2004","unstructured":"Scholey AB, Parrott AC, Buchanan T, Heffernan TM, Ling J, Rodgers J (2004). Increased intensity of ecstasy and polydrug usage in the more experienced recreational ecstasy\/MDMA users: a WWW study. Addict Behav 29: 743\u2013752.","journal-title":"Addict Behav"},{"key":"BF1300896_CR29","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/sj.npp.1300247","volume":"28","author":"DS Segal","year":"2003","unstructured":"Segal DS, Kuczenski R, O\u2019Neil ML, Melega WP, Cho AK (2003). Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28: 1730\u20131740.","journal-title":"Neuropsychopharmacology"},{"key":"BF1300896_CR30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1360-0443.1994.tb03330.x","volume":"89","author":"T Steele","year":"1994","unstructured":"Steele T, McCann U, Ricaurte G (1994). 3,4-Methylenedioxymethamphetamine (MDMA, \u2018ecstasy\u2019): pharmacology and toxicology in animals and humans. Br J Addict 89: 539\u2013551.","journal-title":"Br J Addict"},{"key":"BF1300896_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0376-8716(99)00002-2","volume":"55","author":"L Topp","year":"1999","unstructured":"Topp L, Hando J, Dillon P, Roche A, Solowij N (1999). Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55: 105\u2013115.","journal-title":"Drug Alcohol Depend"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/1300896.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1300896","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1300896.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T16:23:01Z","timestamp":1736007781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1300896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,28]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["BF1300896"],"URL":"https:\/\/doi.org\/10.1038\/sj.npp.1300896","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,28]]}}}